MX2024000022A - Compuestos terapeuticos. - Google Patents
Compuestos terapeuticos.Info
- Publication number
- MX2024000022A MX2024000022A MX2024000022A MX2024000022A MX2024000022A MX 2024000022 A MX2024000022 A MX 2024000022A MX 2024000022 A MX2024000022 A MX 2024000022A MX 2024000022 A MX2024000022 A MX 2024000022A MX 2024000022 A MX2024000022 A MX 2024000022A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic compounds
- compounds
- formula
- disclosed
- salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213519P | 2021-06-22 | 2021-06-22 | |
| PCT/US2022/034374 WO2022271723A1 (en) | 2021-06-22 | 2022-06-21 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000022A true MX2024000022A (es) | 2024-03-15 |
Family
ID=84544904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000022A MX2024000022A (es) | 2021-06-22 | 2022-06-21 | Compuestos terapeuticos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240317749A1 (enExample) |
| EP (1) | EP4359416A4 (enExample) |
| JP (1) | JP2024524213A (enExample) |
| KR (1) | KR20240067229A (enExample) |
| CN (1) | CN118251394A (enExample) |
| AU (1) | AU2022297426A1 (enExample) |
| CA (1) | CA3225427A1 (enExample) |
| IL (1) | IL309569A (enExample) |
| MX (1) | MX2024000022A (enExample) |
| WO (1) | WO2022271723A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117815240A (zh) * | 2023-12-11 | 2024-04-05 | 兰州大学 | 一类具有二氨基吡咯并喹唑啉结构的化合物在防治奶牛乳腺炎致病菌中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2436524T3 (es) * | 2003-05-22 | 2014-01-02 | Nerviano Medical Sciences S.R.L. | Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas |
| US8673929B2 (en) * | 2006-07-20 | 2014-03-18 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| US20090227575A1 (en) * | 2008-03-04 | 2009-09-10 | Wyeth | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS |
| BR112013008527A2 (pt) * | 2010-12-17 | 2016-07-12 | Nerviano Medical Sciences Srl | derivados de pirazolo-quinazolina substituídos como inibidores de cinase |
| US12428423B2 (en) * | 2017-04-01 | 2025-09-30 | Shengke Pharmaceuticals (Jiangsu) Ltd. | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor |
| US11077109B2 (en) * | 2017-08-01 | 2021-08-03 | The Trustees Of Princeton University | Compounds having antibacterial activity and methods of use |
| KR102464677B1 (ko) * | 2017-08-11 | 2022-11-10 | 셍커 파마슈티컬스 (지앙수) 엘티디. | 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물 |
| CN119455003A (zh) * | 2019-02-12 | 2025-02-18 | Ambrx公司 | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 |
| WO2022040596A1 (en) * | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
| EP4204093A1 (en) * | 2020-08-27 | 2023-07-05 | Shengke Pharmaceuticals (Jiangsu) Ltd. | 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors |
-
2022
- 2022-06-21 IL IL309569A patent/IL309569A/en unknown
- 2022-06-21 WO PCT/US2022/034374 patent/WO2022271723A1/en not_active Ceased
- 2022-06-21 US US18/572,411 patent/US20240317749A1/en active Pending
- 2022-06-21 EP EP22829168.8A patent/EP4359416A4/en active Pending
- 2022-06-21 AU AU2022297426A patent/AU2022297426A1/en active Pending
- 2022-06-21 CN CN202280057092.XA patent/CN118251394A/zh active Pending
- 2022-06-21 KR KR1020247002091A patent/KR20240067229A/ko active Pending
- 2022-06-21 CA CA3225427A patent/CA3225427A1/en active Pending
- 2022-06-21 JP JP2023578915A patent/JP2024524213A/ja active Pending
- 2022-06-21 MX MX2024000022A patent/MX2024000022A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022271723A1 (en) | 2022-12-29 |
| EP4359416A1 (en) | 2024-05-01 |
| AU2022297426A1 (en) | 2024-02-01 |
| JP2024524213A (ja) | 2024-07-05 |
| US20240317749A1 (en) | 2024-09-26 |
| CA3225427A1 (en) | 2022-12-29 |
| IL309569A (en) | 2024-02-01 |
| CN118251394A (zh) | 2024-06-25 |
| KR20240067229A (ko) | 2024-05-16 |
| EP4359416A4 (en) | 2025-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| DOP2025000245A (es) | Inhibidores de kras | |
| JOP20230316B1 (ar) | N-(هيدروكسي ألكيل أريل (غير متجانس)) تترا هيدروفيوران كربوكساميدات كمعدلات لقنوات الصوديوم | |
| CY1125784T1 (el) | Υποκατεστημενες δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της prmt5 | |
| CY1124404T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| AR133985A1 (es) | Inhibidores de kras | |
| JOP20230113A1 (ar) | مشتقات ثلاثية الكربوكساميد كمثبطات prmt5 | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EA202092263A1 (ru) | Аминопиридиновые производные в качестве ингибиторов ctps1 | |
| CY1123025T1 (el) | Αναστολεις βρωμοεπικρατειας | |
| JOP20240165A1 (ar) | مشتقات بيبريدينيل سبيرو سيكليك كمثبطات عامل مكمل b واستخداماتها | |
| MX2020007014A (es) | Compuestos de benzamida. | |
| MX386103B (es) | Inhibidores de mcl-1 y metodos de uso de los mismos. | |
| EA202191104A1 (ru) | Производные аминопиридина/пиразина в качестве ингибиторов ctps1 | |
| JOP20190174B1 (ar) | مثبطات jak1 انتقائية | |
| GEAP202516632A (en) | Heteroaryl compounds for the treatment of pain | |
| EA201291356A1 (ru) | Пиперидиноновые производные как ингибиторы mdm2 для лечения рака | |
| EA202190657A1 (ru) | Ингибиторы саркомера сердца | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| UY40235A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| EA201690752A1 (ru) | Ингибиторы g12c kras |